Table 3 Factors potentially implicated in response to radioiodine treatment
From: Radioiodine treatment for graves’ disease: a 10-year Australian cohort study
Remission (n = 73) | No Remission (n = 19) | P | |
|---|---|---|---|
TSH receptor antibody (IU/L)a | 7.2 (4.5–9) | 18 (5.4–68) | 0.02 |
Technetium Uptake (%) | 4.3 (3.1–5.2) | 3.5 (1.8–7.1) | 0.35 |
I131 administered activity (MBq) | 500 (500–511) | 501 (499–505) | 0.58 |
Duration of medical therapy (months) | 21 (12–24) | 36 (6–48) | 0.31 |
Duration of disease (years) | 3 (2–4) | 3 (1–4) | 0.88 |
Pre-Treatment FT4 (pmol/L) | 34 (27–39.9) | 28.9 (19.6–42) | 0.33 |